SciSparc Ltd. (NASDAQ:SPRC) Sees Large Growth in Short Interest

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 155,400 shares, a growth of 61.9% from the November 30th total of 96,000 shares. Approximately 1.5% of the company’s stock are short sold. Based on an average trading volume of 725,400 shares, the short-interest ratio is currently 0.2 days.

Institutional Investors Weigh In On SciSparc

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC acquired a new stake in shares of SciSparc Ltd. (NASDAQ:SPRC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned approximately 5.59% of SciSparc as of its most recent SEC filing. 25.06% of the stock is currently owned by institutional investors.

SciSparc Trading Down 14.2 %

NASDAQ SPRC traded down $0.07 during trading hours on Friday, reaching $0.43. 8,035,851 shares of the company traded hands, compared to its average volume of 2,476,734. SciSparc has a 12 month low of $0.20 and a 12 month high of $6.78. The company has a 50 day moving average of $0.24 and a two-hundred day moving average of $0.39.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.